ContraFect Corporation (CFRX)
CFRXPrice: $0.05
Fair Value: 🔒
🔒score
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead program includes Exebacase, a lysin, which is in Phase III clin... more
ContraFect Corporation, a clinical-stage biotechnology company, discovers and develops therapeutic p... more
Description
Shares
| Market Cap | $0 | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Michael Messinger CPA |
| IPO Date | 2014-09-12 | CAGR | — |
| Employees | 23 | Website | www.contrafect.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
CFRX chart loading...
Fundamentals
Technicals
| Enterprise Value | $3.24M | P/E Ratio | -0 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | — |
| P/CF Ratio | — | P/FCF Ratio | — |
| EPS | $-10.83 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -100% | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -3.47% | ROA | -3.15% |
| ROCE | 353.35% | Current Ratio | 0.85 |
| Quick Ratio | 0.85 | Cash Ratio | 0.43 |
| Debt/Equity | -0.24 | Interest Coverage | — |
| Altman Z Score | -60.87 | Piotroski Score | 1 |